Testing two oral treatments for cutaneous leishmaniasis
Treatments studied
Part of Infections, Skin clinical trials.
This study tests two new oral medicines compared to an existing oral medicine for people with a first episode of cutaneous leishmaniasis (skin sores caused by a parasite). It aims to find a more effective and convenient treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and weigh more than 110 pounds (50 kg).
- This is your first time having cutaneous leishmaniasis, with up to 6 skin sores, at least one larger than a pea (50 mm²), and sores started within the last 6 months.
- Your diagnosis is confirmed by a lab test (like PCR or microscope).
- You are not pregnant, breastfeeding, or planning to become pregnant, and agree to use effective birth control.
- You do not have severe health problems like heart, kidney, liver disease, or a weakened immune system (such as uncontrolled HIV).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different drugs to find which works best for cutaneous leishmaniasis (a skin infection from a parasite). It may help people with many or large sores, or sores in sensitive areas like near the eyes or nose.
This trial tests if oral medicines can treat cutaneous (skin) or mucosal leishmaniasis in people aged 60 and older. It compares two different pills to find a safer, easier option for elderly patients.
This trial tests how well miltefosine works for people with leishmaniasis, a skin infection from a parasite. It aims to find the best way to use this medicine to help patients get better.
This study tests a gel form of miltefosine applied directly to skin sores caused by leishmaniasis. It is for adults with mild to moderate skin infections who have not already tried and failed other treatments.
This trial tests a combination of two medicines—inhaled pentamidine and oral miltefosine—to treat mucosal leishmaniasis, a parasitic infection of the nose, mouth, and throat. It may be an option for people in Bolivia who have not been treated recently.
This trial compares two approaches for treating skin sores caused by Leishmania: standard injections alone versus injections plus a laser treatment. It aims to see if adding laser therapy improves healing.
Hear when a new Localized Cutaneous Leishmaniasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.